61.53

4.77% 2.80

After Hours: 61.53

Bio Techne Corp (TECH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Bio Techne Corp stock is traded at $61.53, with a volume of 1.96M. It is up +4.77% in the last 24 hours and down -3.04% over the past month. Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Previous Close:

$58.73

Open:

$58.83

24h Volume:

1.96M

Relative Volume:

0.86

Market Cap:

$9.59B

Revenue:

$1.17B

Net Income/Loss:

$150.71M

P/E Ratio:

65.46

EPS:

0.94

Net Cash Flow:

$245.03M

1W Performance:

+3.62%

1M Performance:

-3.04%

6M Performance:

+31.87%

1Y Performance:

-13.40%

1-Day Range:

$58.42

$62.56

1-Week Range:

$57.02

$62.56

52-Week Range:

$46.01

$79.28

Bio Techne Corp Stock (TECH) Company Profile

Name

Bio Techne Corp

Sector

Healthcare (1129)

Industry

Biotechnology (632)

Phone

612-379-8854

Address

614 MCKINLEY PL N E, MINNEAPOLIS, MN

Employee

3,100

Twitter

@biotechne

Next Earnings Date

2024-10-30

Latest SEC Filings

TECH's Discussions on Twitter

Compare TECH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TECH Bio Techne Corp	61.53	9.15B	1.17B	150.71M	245.03M	0.94
VRTX Vertex Pharmaceuticals Inc	426.76	107.15B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	755.90	77.46B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	436.38	58.90B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	918.92	56.55B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	198.76	42.58B	447.02M	-1.18B	-906.14M	-6.1812

Bio Techne Corp Stock (TECH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-03-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Aug-21-25	Upgrade	Citigroup	Neutral → Buy
Jul-22-25	Resumed	Stephens	Overweight
Jul-09-25	Initiated	TD Cowen	Buy
May-30-25	Initiated	Wells Fargo	Overweight
Apr-09-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Mar-18-25	Initiated	Evercore ISI	Outperform
Feb-19-25	Downgrade	Robert W. Baird	Outperform → Neutral
May-22-24	Downgrade	Citigroup	Buy → Neutral
Feb-08-24	Initiated	Scotiabank	Sector Outperform
Feb-02-24	Downgrade	Stifel	Buy → Hold
Dec-07-23	Initiated	UBS	Buy
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform
Aug-25-22	Initiated	Credit Suisse	Outperform
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight
Sep-15-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-08-21	Upgrade	Stephens	Equal-Weight → Overweight
Feb-23-21	Upgrade	Stifel	Hold → Buy
Jan-25-21	Reiterated	The Benchmark Company	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-30-20	Initiated	Atlantic Equities	Overweight
Jul-15-20	Downgrade	Stephens	Overweight → Equal-Weight
May-27-20	Downgrade	Stifel	Buy → Hold
May-14-20	Initiated	The Benchmark Company	Buy
Jan-08-20	Resumed	Stephens	Overweight
Jan-08-20	Initiated	Wells Fargo	Equal Weight
Jan-07-20	Initiated	Citigroup	Neutral
Nov-15-19	Initiated	Stifel	Buy
Jul-02-19	Upgrade	Janney	Neutral → Buy
Jan-14-19	Upgrade	Stephens	Equal-Weight → Overweight
Oct-31-18	Downgrade	Craig Hallum	Buy → Hold
Oct-17-18	Initiated	Goldman	Neutral
Jun-15-18	Initiated	Argus	Buy
Jul-13-17	Initiated	Wells Fargo	Market Perform
Feb-09-17	Initiated	Citigroup	Buy
Jan-18-17	Initiated	Deutsche Bank	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Jan-21-15	Reiterated	Robert W. Baird	Outperform
Sep-20-13	Upgrade	Robert W. Baird	Neutral → Outperform

View All

Bio Techne Corp Stock (TECH) Latest News

Nov 22, 2025

Creative Planning Has $4.29 Million Stock Holdings in Bio-Techne Corp $TECH - MarketBeat

Nov 22, 2025

Nov 21, 2025

Envista, Alignment Healthcare, LifeStance Health Group, Avantor, and Bio-Techne Shares Are Soaring, What You Need To Know - Finviz

Nov 21, 2025

First Week of July 2026 Options Trading For Bio-Techne (TECH) - Nasdaq

Nov 21, 2025

Catalyst Funds Management Pty Ltd Boosts Stock Holdings in Bio-Techne Corp $TECH - MarketBeat

Nov 21, 2025

Exclusive AI-Designed Protein Access Might Change the Case for Investing in Bio-Techne (TECH) - Yahoo! Finance Canada

Nov 21, 2025

Nov 20, 2025

Bio-Techne at Jefferies Conference: Strategic Insights and Innovations - Investing.com

Nov 20, 2025

Can Bio Techne Corporation (TE1) stock sustain breakout momentumForecast Cut & AI Forecast for Swing Trade Picks - newser.com

Nov 20, 2025

Will Bio Techne Corporation (TE1) stock boost dividends further2025 Breakouts & Breakdowns & Precise Buy Zone Tips - newser.com

Nov 20, 2025

Nov 19, 2025

Will Bio Techne Corporation stock split attract more investorsShare Buyback & Precise Trade Entry Recommendations - newser.com

Nov 19, 2025

How Bio Techne Corporation (TE1) stock benefits from digital adoption2025 Analyst Calls & Consistent Profit Trade Alerts - newser.com

Nov 19, 2025

Can Bio Techne Corporation (TE1) stock deliver double digit returnsJuly 2025 Price Swings & High Accuracy Trade Signal Alerts - newser.com

Nov 19, 2025

Rothschild Investment LLC Purchases 17,529 Shares of Bio-Techne Corp $TECH - MarketBeat

Nov 19, 2025

Bio-Techne Corporation (TECH) stock price, news, quote and history - Yahoo Finance UK

Nov 19, 2025